Halozyme Therapeutics (NASDAQ:HALO) Earns “Buy” Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Halozyme Therapeutics (NASDAQ:HALO) in a research report sent to investors on Friday, Benzinga reports. They currently have a $65.00 price target on the biopharmaceutical company’s stock.

HALO has been the topic of several other reports. Benchmark reaffirmed a buy rating and set a $60.00 price target on shares of Halozyme Therapeutics in a research note on Thursday, August 8th. Morgan Stanley lifted their target price on shares of Halozyme Therapeutics from $59.00 to $64.00 and gave the stock an overweight rating in a research note on Wednesday, August 7th. Wells Fargo & Company increased their price target on Halozyme Therapeutics from $48.00 to $58.00 and gave the stock an overweight rating in a research note on Friday, June 7th. Piper Sandler cut Halozyme Therapeutics from an overweight rating to a neutral rating and raised their price objective for the stock from $48.00 to $51.00 in a report on Friday, June 7th. Finally, TD Cowen upped their target price on Halozyme Therapeutics from $59.00 to $65.00 and gave the company a buy rating in a research note on Wednesday, August 7th. Three analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of Moderate Buy and an average price target of $60.00.

Halozyme Therapeutics Trading Down 2.1 %

Shares of HALO opened at $59.18 on Friday. The company has a debt-to-equity ratio of 5.19, a current ratio of 7.41 and a quick ratio of 6.21. Halozyme Therapeutics has a 1-year low of $32.83 and a 1-year high of $65.53. The stock has a market cap of $7.53 billion, a price-to-earnings ratio of 24.45, a price-to-earnings-growth ratio of 0.56 and a beta of 1.27. The firm has a 50 day simple moving average of $58.96 and a 200-day simple moving average of $50.42.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.91 earnings per share for the quarter, topping the consensus estimate of $0.73 by $0.18. Halozyme Therapeutics had a return on equity of 195.80% and a net margin of 38.62%. The company had revenue of $231.40 million during the quarter, compared to the consensus estimate of $204.94 million. During the same quarter last year, the business posted $0.68 earnings per share. Halozyme Therapeutics’s revenue was up 4.7% compared to the same quarter last year. Equities analysts forecast that Halozyme Therapeutics will post 3.71 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Helen Torley sold 10,000 shares of Halozyme Therapeutics stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $59.20, for a total value of $592,000.00. Following the transaction, the chief executive officer now directly owns 676,744 shares of the company’s stock, valued at $40,063,244.80. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. In other Halozyme Therapeutics news, CEO Helen Torley sold 10,000 shares of the company’s stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $59.20, for a total value of $592,000.00. Following the completion of the transaction, the chief executive officer now owns 676,744 shares in the company, valued at $40,063,244.80. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Nicole Labrosse sold 5,000 shares of the business’s stock in a transaction on Monday, July 22nd. The stock was sold at an average price of $53.93, for a total transaction of $269,650.00. Following the completion of the transaction, the chief financial officer now owns 15,480 shares in the company, valued at $834,836.40. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 84,881 shares of company stock worth $4,932,284 over the last three months. 2.40% of the stock is owned by insiders.

Institutional Trading of Halozyme Therapeutics

Several institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. raised its stake in shares of Halozyme Therapeutics by 1.2% in the 4th quarter. Vanguard Group Inc. now owns 13,259,514 shares of the biopharmaceutical company’s stock valued at $490,072,000 after purchasing an additional 152,870 shares in the last quarter. TD Asset Management Inc lifted its stake in Halozyme Therapeutics by 28.1% during the first quarter. TD Asset Management Inc now owns 2,541,266 shares of the biopharmaceutical company’s stock worth $103,379,000 after purchasing an additional 557,350 shares during the last quarter. Handelsbanken Fonder AB boosted its holdings in Halozyme Therapeutics by 76.9% in the third quarter. Handelsbanken Fonder AB now owns 1,969,169 shares of the biopharmaceutical company’s stock worth $112,715,000 after purchasing an additional 856,200 shares during the period. Dimensional Fund Advisors LP increased its stake in Halozyme Therapeutics by 12.4% during the second quarter. Dimensional Fund Advisors LP now owns 1,897,759 shares of the biopharmaceutical company’s stock valued at $99,363,000 after purchasing an additional 209,530 shares during the last quarter. Finally, Epoch Investment Partners Inc. raised its holdings in shares of Halozyme Therapeutics by 23.3% during the first quarter. Epoch Investment Partners Inc. now owns 1,433,612 shares of the biopharmaceutical company’s stock worth $58,319,000 after purchasing an additional 270,579 shares during the period. 97.79% of the stock is owned by institutional investors and hedge funds.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.